TABLE 2.
Agglutination phenotypes associated with PapG variants and S fimbriae
| Adhesina | Agglutination intensity
|
HA inhibition (A1P1 RBC)c
|
Neuraminidase sensitivity of HAc
|
||||||
|---|---|---|---|---|---|---|---|---|---|
| A1P1, OP1, or pig RBCb | Sheep RBC | Pk1 RBC | P beads | Pigeon egg white | Fetuin | A1P1 RBC | OP1 RBC | Sheep RBC | |
| PapG III | +++ | ++++ | − | − | Yes | No | No | Vard | No |
| PapG II | ++++ | +++ | +++ | +++ | Yes | No | No | Var | No |
| PapG I + III | ++++ | ++++ | +++ | ++++ | Yes | No | No | Var | No |
| PapG I | +++ | + | ++ | +++ | Yes | No | No | Var | NAe |
| PapG I′ | +++ | ++++ | ++ | +++ | Yes | No | No | Yes | No |
| S fimbriae | +++ | +++ | ++ | − | No | Yes | Yes | Nof | Yes |
a
Strains used included BOS080, BOS060, and P678-54/pJFK102 (PapG III), IA2 and HB101/pDC1 (PapG II), J96 (PapG I + III), P678-54/pRHU845 (PapG I), L31 (PapG I′), and HU968-298 (S fimbriae).
b
RBC, erythrocytes. A1P1, OP1, and Pk1 RBC are from human donors.
c
HA, hemagglutination. Inhibition and sensitivity defined as at least a two-level decrease in agglutination intensity (strongest to weakest, ++++ to −) in the presence of inhibitor or after neuraminidase digestion, respectively.
d
var., variable between experiments.
e
NA, not applicable (no HA of sheep RBC).
f
HA intensity decreased by one intensity level with neuraminidase digestion in both of two trials.